Cargando…
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
SIMPLE SUMMARY: Thus far, clinical studies have shown that immunotherapy (atezolizumab-bevacizumab) has shown better and favorable overall survival than sorafenib for advanced hepatocellular carcinoma (HCC). However, the treatment outcomes of hepatic arterial infusion chemotherapy (HAIC) with cispla...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582478/ https://www.ncbi.nlm.nih.gov/pubmed/34771452 http://dx.doi.org/10.3390/cancers13215282 |
_version_ | 1784596995634102272 |
---|---|
author | Zaizen, Yuki Nakano, Masahito Fukumori, Kazuta Yano, Yoichi Takaki, Kota Niizeki, Takashi Kuwaki, Kotaro Fukahori, Masaru Sakaue, Takahiko Yoshimura, Sohei Nakazaki, Mika Kuromatsu, Ryoko Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Shirono, Tomotake Noda, Yu Kamachi, Naoki Koga, Hironori Torimura, Takuji |
author_facet | Zaizen, Yuki Nakano, Masahito Fukumori, Kazuta Yano, Yoichi Takaki, Kota Niizeki, Takashi Kuwaki, Kotaro Fukahori, Masaru Sakaue, Takahiko Yoshimura, Sohei Nakazaki, Mika Kuromatsu, Ryoko Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Shirono, Tomotake Noda, Yu Kamachi, Naoki Koga, Hironori Torimura, Takuji |
author_sort | Zaizen, Yuki |
collection | PubMed |
description | SIMPLE SUMMARY: Thus far, clinical studies have shown that immunotherapy (atezolizumab-bevacizumab) has shown better and favorable overall survival than sorafenib for advanced hepatocellular carcinoma (HCC). However, the treatment outcomes of hepatic arterial infusion chemotherapy (HAIC) with cisplatin compared with sorafenib for intrahepatic advanced HCC remain unclear. We therefore aimed to determine the prognostic factors for HAIC with cisplatin. Our results showed that HAIC with cisplatin could significantly prolong the overall survival for intrahepatic advanced HCC and had a longer prognostic effect than sorafenib. Therefore, our results suggest that HAIC should be used in intrahepatic advanced HCC. ABSTRACT: Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; p = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; p = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; p = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC. |
format | Online Article Text |
id | pubmed-8582478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85824782021-11-12 Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis Zaizen, Yuki Nakano, Masahito Fukumori, Kazuta Yano, Yoichi Takaki, Kota Niizeki, Takashi Kuwaki, Kotaro Fukahori, Masaru Sakaue, Takahiko Yoshimura, Sohei Nakazaki, Mika Kuromatsu, Ryoko Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Shirono, Tomotake Noda, Yu Kamachi, Naoki Koga, Hironori Torimura, Takuji Cancers (Basel) Article SIMPLE SUMMARY: Thus far, clinical studies have shown that immunotherapy (atezolizumab-bevacizumab) has shown better and favorable overall survival than sorafenib for advanced hepatocellular carcinoma (HCC). However, the treatment outcomes of hepatic arterial infusion chemotherapy (HAIC) with cisplatin compared with sorafenib for intrahepatic advanced HCC remain unclear. We therefore aimed to determine the prognostic factors for HAIC with cisplatin. Our results showed that HAIC with cisplatin could significantly prolong the overall survival for intrahepatic advanced HCC and had a longer prognostic effect than sorafenib. Therefore, our results suggest that HAIC should be used in intrahepatic advanced HCC. ABSTRACT: Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; p = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; p = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; p = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC. MDPI 2021-10-21 /pmc/articles/PMC8582478/ /pubmed/34771452 http://dx.doi.org/10.3390/cancers13215282 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zaizen, Yuki Nakano, Masahito Fukumori, Kazuta Yano, Yoichi Takaki, Kota Niizeki, Takashi Kuwaki, Kotaro Fukahori, Masaru Sakaue, Takahiko Yoshimura, Sohei Nakazaki, Mika Kuromatsu, Ryoko Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Shirono, Tomotake Noda, Yu Kamachi, Naoki Koga, Hironori Torimura, Takuji Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title_full | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title_fullStr | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title_full_unstemmed | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title_short | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
title_sort | hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for intrahepatic advanced hepatocellular carcinoma: a propensity score-matched analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582478/ https://www.ncbi.nlm.nih.gov/pubmed/34771452 http://dx.doi.org/10.3390/cancers13215282 |
work_keys_str_mv | AT zaizenyuki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT nakanomasahito hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT fukumorikazuta hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yanoyoichi hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takakikota hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT niizekitakashi hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kuwakikotaro hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT fukahorimasaru hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT sakauetakahiko hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yoshimurasohei hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT nakazakimika hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kuromatsuryoko hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT okamurashusuke hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT iwamotohideki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shimoseshigeo hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shironotomotake hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT nodayu hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kamachinaoki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kogahironori hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT torimuratakuji hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis |